Equities Analysts Set Expectations for Exelixis Q3 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Zacks Research cut their Q3 2026 earnings per share estimates for Exelixis in a research note issued to investors on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.62 for the quarter, down from their previous estimate of $0.63. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2026 earnings at $2.48 EPS, Q2 2027 earnings at $0.75 EPS and FY2027 earnings at $3.07 EPS.

A number of other brokerages also recently commented on EXEL. Barclays boosted their price objective on shares of Exelixis from $29.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 10th. Truist Financial cut their price target on Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. Bank of America upped their price objective on Exelixis from $45.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, June 5th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Tuesday, July 29th. Finally, Benchmark reiterated a “neutral” rating on shares of Exelixis in a report on Monday, June 23rd. Thirteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $44.06.

Exelixis Stock Performance

NASDAQ:EXEL opened at $37.42 on Monday. The firm has a 50-day simple moving average of $41.15 and a 200-day simple moving average of $39.54. Exelixis has a one year low of $25.12 and a one year high of $49.62. The firm has a market cap of $10.07 billion, a P/E ratio of 17.99, a P/E/G ratio of 0.77 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently modified their holdings of EXEL. Centaurus Financial Inc. purchased a new stake in Exelixis during the 2nd quarter worth approximately $274,000. Orion Porfolio Solutions LLC lifted its stake in shares of Exelixis by 20.0% during the second quarter. Orion Porfolio Solutions LLC now owns 55,301 shares of the biotechnology company’s stock worth $2,437,000 after buying an additional 9,224 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of Exelixis by 32.9% during the second quarter. Neuberger Berman Group LLC now owns 31,406 shares of the biotechnology company’s stock valued at $1,384,000 after buying an additional 7,779 shares during the last quarter. Advisory Services Network LLC increased its position in shares of Exelixis by 38.6% in the 2nd quarter. Advisory Services Network LLC now owns 40,698 shares of the biotechnology company’s stock valued at $1,794,000 after acquiring an additional 11,334 shares during the period. Finally, Cim LLC purchased a new position in Exelixis in the 2nd quarter worth $1,547,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.